On September 16, 2026 Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), reported that the U.S. Patent and Trademark Office (USPTO) has officially granted a patent (Patent No. US12,735,481) for its proprietary, core bispecific antibody technology platform, PACbody (PAC = Pairing of Alternative Cysteines). This patent grant marks a significant milestone for Phanes in its foundational bispecific technology and global intellectual property protection.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PACbody is a proprietary bispecific antibody construction platform internally discovered and owned by Phanes. It enables the generation of bispecific antibodies that maintain native IgG structures with drug-like CMC characteristics. Bispecific antibodies built on this platform exhibit excellent manufacturability, including stability, high expression, and seamless compatibility with conventional monoclonal antibody commercial manufacturing processes, significantly reducing development, clinical, and manufacturing risks.
Innovative bispecific antibodies developed using the PACbody platform have demonstrated robust clinical potential. Most notably, Phanes’ core asset spevatamig (PT886) has advanced into Phase II clinical trials and showed positive results, as reported at the ASCO (Free ASCO Whitepaper) Annual Meeting in May 2026. Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted by the FDA orphan drug designation (ODD) for the treatment of pancreatic cancer in 2022, Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024, and recently, Fast Track designation for the treatment of advanced and metastatic biliary tract carcinoma. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab. Spevatamig is an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. It has the potential to become the first I2E for a solid tumor indication and is combinable with various anti-cancer therapies.
"We are thrilled that our PACbody platform has been granted this U.S. patent," said Dr. Ming Wang, Founder and CEO of Phanes Therapeutics. "PACbody is our core technology for overcoming the CMC challenges that typically hindered bispecific antibody development. This patent approval not only validates our top-tier innovative R&D capabilities but also significantly strengthens the protection of our core pipeline’s intellectual property. We will continue to leverage this platform to accelerate the delivery of safer and more effective breakthrough therapies to cancer patients worldwide."
(Press release, Phanes Therapeutics, SEP 16, 2026, View Source [SID1234670905])